Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatmen… Read more
Aktis Oncology, Inc. Common stock (AKTS) - Total Assets
Latest total assets as of September 2025: $279.04 Million USD
Based on the latest financial reports, Aktis Oncology, Inc. Common stock (AKTS) holds total assets worth $279.04 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aktis Oncology, Inc. Common stock - Total Assets Trend (2013–2024)
This chart illustrates how Aktis Oncology, Inc. Common stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aktis Oncology, Inc. Common stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Aktis Oncology, Inc. Common stock's total assets of $279.04 Million consist of 92.2% current assets and 7.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.4% |
| Accounts Receivable | $5.29 Million | 1.6% |
| Inventory | $2.22 Million | 0.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $12.56 Million | 3.9% |
| Goodwill | $6.51 Million | 2.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Aktis Oncology, Inc. Common stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aktis Oncology, Inc. Common stock's current assets represent 92.2% of total assets in 2024, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2024, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 3.9% of total assets.
Aktis Oncology, Inc. Common stock Competitors by Total Assets
Key competitors of Aktis Oncology, Inc. Common stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Aktis Oncology, Inc. Common stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Aktis Oncology, Inc. Common stock generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Aktis Oncology, Inc. Common stock is currently not profitable relative to its asset base.
Aktis Oncology, Inc. Common stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.27 | 18.55 | 9.40 |
| Quick Ratio | 9.27 | 18.36 | 9.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $222.51 Million | $ 298.41 Million | $ 35.10 Million |
Aktis Oncology, Inc. Common stock - Advanced Valuation Insights
This section examines the relationship between Aktis Oncology, Inc. Common stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 367.7% |
| Total Assets | $326.18 Million |
| Market Capitalization | $9.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aktis Oncology, Inc. Common stock's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aktis Oncology, Inc. Common stock's assets grew by 367.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aktis Oncology, Inc. Common stock (2013–2024)
The table below shows the annual total assets of Aktis Oncology, Inc. Common stock from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $326.18 Million | +367.70% |
| 2024-06-30 | $69.74 Million | -43.00% |
| 2023-12-31 | $122.36 Million | -17.84% |
| 2023-06-30 | $148.92 Million | +7.66% |
| 2022-12-31 | $138.32 Million | -14.27% |
| 2022-06-30 | $161.34 Million | 0.00% |
| 2021-12-31 | $161.34 Million | +29.08% |
| 2021-06-30 | $124.99 Million | +74.98% |
| 2020-12-31 | $71.43 Million | 0.00% |
| 2020-06-30 | $71.43 Million | +48.98% |
| 2019-12-31 | $47.95 Million | 0.00% |
| 2019-06-30 | $47.95 Million | +63.60% |
| 2018-12-31 | $29.31 Million | 0.00% |
| 2018-06-30 | $29.31 Million | +61.99% |
| 2017-12-31 | $18.09 Million | 0.00% |
| 2017-06-30 | $18.09 Million | +298.27% |
| 2016-06-30 | $4.54 Million | 0.00% |
| 2015-12-31 | $4.54 Million | +0.66% |
| 2015-06-30 | $4.51 Million | 0.00% |
| 2014-12-31 | $4.51 Million | +47297.76% |
| 2014-06-30 | $9.52K | +4.63% |
| 2013-12-31 | $9.10K | 0.00% |
| 2013-06-30 | $9.10K | -- |